90 results found.

Management of Anemia in Chronic Kidney Disease Patients Not on Di Clinical Trial using Darbepoetin alfa

Amgen - Recruiting 18 years or older.
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease.
Darbepoetin alfa

Chronic Renal Failure Requiring Hemodialysis Clinical Trial using Epoetin Hospira

Hospira, Inc. - Recruiting 18 years to 80 years.
- A Phase 3 Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment.
Epoetin Hospira

Non-Small Cell Lung Cancer, Anemia, Cancer, or Lung Cancer Clinical Trial using darbepoetin alfa 500 mcg Q3W; placebo

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
darbepoetin alfa 500 mcg Q3W; placebo

Anemia, or Kidney Failure, Chronic Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoiesis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept.
Sotatercept

Dyskeratosis Congenita, or Aplastic Anemia Clinical Trial using Campath 1H; Cyclophosphamide; Fludarabine; Total Body Irradiation; Stem Cell Transplantation; antithymocyte globulin; Methylprednisolone

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 70 years.
- Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia.
Campath 1H; Cyclophosphamide; Fludarabine; Total Body Irradiation; Stem Cell Transplantation; antithymocyte globulin; Methylprednisolone

Diamond Blackfan Anemia Clinical Trial using Sotatercept

North Shore Long Island Jewish Health System - Recruiting 18 years or older.
- Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia.
Sotatercept

Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disea Clinical Trial using Hepatic biomagnetic susceptibility measurement

Columbia University - Recruiting 5 years to 80 years.
- High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device).
Hepatic biomagnetic susceptibility measurement

Myelodysplastic Syndrome Clinical Trial using Oral Azacitidine; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Oral Azacitidine; Placebo

Neonatal Anemia Clinical Trial using Transfused Biotin RBCs - Adults Phase I; Transfused Biotin RBCs - Infants Phase II; Transfused Biotin RBCs - Infants Phase III

University of Iowa - Recruiting N/A to 6 Months.
- Red Blood Cell Survival Following Transfusion in Infants.
Transfused Biotin RBCs - Adults Phase I; Transfused Biotin RBCs - Infants Phase II; Transfused Biotin RBCs - Infants Phase III

Anemia Clinical Trial using Ferinjectr; normal saline

National Cancer Center, Korea - Recruiting 19 years or older.
- A Randomized Patient -Blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinjectr) With Placebo in Patients With Acute Isovolemic Anemia After Gastrectomy.
Ferinjectr; normal saline

Acute Blood Loss Anemia, or Osteoarthritis, Hip Clinical Trial using Transexamic Acid; Placebo

Henry Ford Health System - Recruiting 18 years or older.
- Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty.
Transexamic Acid; Placebo

Anemia, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic L Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)..
Sotatercept

Genotype, Pain, Sickle Cell Anemia, or Vaso-Occlusive Pain Crisis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Exploratory Studies of Psychophysical Pain Phenotyping and Genetic Variability in Sickle Cell Disease.

Healthy, or Sickle Cell Anemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 45 years.
- Collection and Storage of Umbilical Cord Hematopoietic Stem Cells for Sickle Cell Disease Therapy.

Aplastic Anemia, Neutropenia, Pancytopenia, Anemia, or Thrombocyt Clinical Trial using Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia.
Eltrombopag; Horse Anti-Thymocyte Globulin (ATG); Cyclosporine A (CSA)

Pulmonary Hypertension, or Sickle Cell Anemia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients With Sickle Cell Anemia.

Congenital Hemolytic Anemia, or Diamond-Blackfan Anemia Clinical Trial using Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia.
Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

Myelodysplastic Syndrome (MDS), Hematologic Neoplasms, Hematologi Clinical Trial using Cord Blood Transplant

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications.
Cord Blood Transplant

Anemia, Sickle Cell Clinical Trial using systematic psychological care

Fondation Ophtalmologique Adolphe de Rothschild - Recruiting N/A to 18 years.
- The Impact of Systematic Psychological and Medical Care for Treatment of Pediatric Patients With SCD: : A Luxury or a Necessity?.
systematic psychological care

Normal Aging, or Anemia Clinical Trial using Biotin RBC survival

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Assessing Mechanisms Accounting for Unexplained Anemia in the Elderly.
Biotin RBC survival

Peripheral Blood Stem Cell Transplantation, Anemia, Sickle Cell, Clinical Trial using PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

Aplastic Anemia, Leukemia, Myelodysplastic Syndrome (MDS), or Lym Clinical Trial using Cord Blood Units

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients.
Cord Blood Units

Severe Aplastic Anemia (SAA) Clinical Trial using Eltrombopag (promacta)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia.
Eltrombopag (promacta)

Anemia, or Chronic Kidney Disease Clinical Trial using AKB-6548; Placebo

Akebia Therapeutics - Recruiting 18 years to 82 years.
- Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis).
AKB-6548; Placebo

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study to Assess the Efficacy of Mircera for Renal Anemia Correction in Dialysis Patients in Everyday Clinical Practice in Poland..

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERAr (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA)..

Anemia, or Renal Insufficiency, Chronic Clinical Trial using BAY85-3934; Darbepoetin alfa

Bayer - Recruiting 18 years or older.
- A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific.
BAY85-3934; Darbepoetin alfa

Anaemia Clinical Trial using GSK1278863; Placebo; rhEPO

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin.
GSK1278863; Placebo; rhEPO

Anaemia Clinical Trial using GSK1278863; rhEPO

GlaxoSmithKline - Recruiting 18 years or older.
- A 24-week, Phase IIB, Randomized, Active-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis..
GSK1278863; rhEPO

Anaemia Clinical Trial using GSK1278863; Placebo

GlaxoSmithKline - Recruiting 20 years or older.
- A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease.
GSK1278863; Placebo

Fanconi's Anemia, Anemia, Diamond Blackfan, Dyskeratosis Congenit Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study.

Anemia Clinical Trial using Short storage RBC age

Washington University School of Medicine - Recruiting N/A to 15 years.
- Age of Blood in Children in Pediatric Intensive Care Units.
Short storage RBC age

Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, or Sickle C Clinical Trial using Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Thomas Jefferson University - Recruiting 18 years to 45 years.
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors.
Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Hip Fracture, or Anemia Clinical Trial using Tranexamic Acid; Placebo

Hvidovre University Hospital - Recruiting 18 years or older.
- Effect of Tranexamic Acid on Blood Loss and Transfusion Need in Patients Operated With a Short Intramedullary Nail, for Pertrochanteric Fractures ..
Tranexamic Acid; Placebo

Aplastic Anemia, Bone Marrow Failure Syndromes, Idiopathic Pulmon Clinical Trial using Nandrolone Decanoate

University of Sao Paulo - Recruiting 2 years or older.
- Male Hormones for Telomere Related Diseases.
Nandrolone Decanoate

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 5 years to 17 years.
- An Open Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis..
methoxy polyethylene glycol-epoetin beta [Mircera]

Sickle Cell Disease Clinical Trial using Alemtuzumab; Fludarabine; Melphalan

Hackensack University Medical Center - Recruiting 2 years to 30 years.
- Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old.
Alemtuzumab; Fludarabine; Melphalan

Anemia, or Chronic Kidney Disease Clinical Trial using Darbepoetin alfa

Amgen - Recruiting N/A to 1 year.
- An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease.
Darbepoetin alfa

Anemia, or Renal Insufficiency, Chronic Clinical Trial using BAY85-3934; Epoetin alfa/beta

Bayer - Recruiting 18 years or older.
- A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan.
BAY85-3934; Epoetin alfa/beta

Iron Deficiency Anemia Clinical Trial using Tardyferon 80 mg

Pierre Fabre Medicament - Recruiting 18 years to 45 years.
- Study of the Pharmacokinetics of Serum Iron After Single Oral Administration of Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia.
Tardyferon 80 mg

Anemia, Kidney Disease, Chronic Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 18 years or older.
- Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients.
methoxy polyethylene glycol-epoetin beta [Mircera]

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis.

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Open Label Study to Assess All-cause Mortality and Cardiovascular Morbidity in Patients With Chronic Kidney Disease on Dialysis and Those Not on Renal Replacement Therapy Under Treatment With Mircera or Reference ESAs..
methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 18 years or older.
- A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Diabetic Nephropathy With CKD Stages III-IV Not on Dialysis, Not Currently Treated With ESA..
methoxy polyethylene glycol-epoetin beta [Mircera]

Renal Anemia, Pregnancy, or Lactation Clinical Trial

Hospira, Inc. - Recruiting N/A or older.
- Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia (PASCO 1I).

Anemia Clinical Trial using HBOC-201

Englewood Hospital and Medical Center - Recruiting 18 years to 80 years.
- Expanded Access Protocol for the Treatment Use of HBOC-201.
HBOC-201

Pregnancy Clinical Trial using Intravaneous iron(low molecular weight iron dextran)

Auerbach Hematology Oncology Associates P C - Recruiting 18 years to 45 years.
- Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron..
Intravaneous iron(low molecular weight iron dextran)

Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia, Neutropenia, Clinical Trial using Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Thomas Jefferson University - Recruiting 18 years or older.
- Compassionate Use of the CliniMACSr CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells.
Allogeneic hematopoietic stem cell transplantation; Peripheral blood stem cell transplantation; Management of therapy complications

Hemoglobin SC Disease, Hematologic Diseases, Sickle Cell Anemia, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Studies of the Natural History of Sickle Cell Disease and Other Hemolytic Disorders.

Sickle Cell Disease, Sickle Cell Anemia, or Anemia, Sickle Cell Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- End-Alveolar Carbon Monoxide as a Measure of Erythrocyte Survival and Hemolytic Severity in Sickle Cell Disease.

Relapsed or Refractory Severe Aplastic Anemia, or Severe Aplastic Clinical Trial using Alemtuzumab (Campath )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia.
Alemtuzumab (Campath )

Aplastic Anemia Clinical Trial using Danazol

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Male Hormones for Telomere Related Diseases.
Danazol

Anemia, Aplastic, or Anemia, Hypoplastic Clinical Trial using h-ATG (ATGAM ); Cyclosporine (Gengraf )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 82 years.
- Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment.
h-ATG (ATGAM ); Cyclosporine (Gengraf )

Aplastic Anemia Clinical Trial using ATG-fresenius

National Institute of Blood Disease Center, Pakistan - Recruiting 2 years to 65 years.
- Protocol for Comparison of Two Different Regimens of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia.
ATG-fresenius

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Chronic Kidney Disease Clinical Trial using Conventional low protein diet; Very low protein diet supplemented with Ketosteril

Anemia Working Group Romania - Recruiting 18 years to 85 years.
- Effect of Very Low Protein Diet Supplemented With Ketoanalogues of the Essential Amino Acids on the Progression of Chronic Kidney Disease.
Conventional low protein diet; Very low protein diet supplemented with Ketosteril

Anemia in Chronic Kidney Disease in Non-dialysis Patients Clinical Trial using FG-4592; Placebo

Astellas Pharma Inc - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
FG-4592; Placebo

Iron Deficiency Anemia, or Malaria Clinical Trial using Iron Supplement

University of North Carolina, Chapel Hill - Recruiting 18 years to 70 years.
- Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum.
Iron Supplement

Gastrointestinal Hemorrhage, or Anemia Clinical Trial using Ferinject 1000 mg; Sodium chlorure 0,9 %

University Hospital, Rouen - Recruiting 65 years or older.
- Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65.
Ferinject 1000 mg; Sodium chlorure 0,9 %

Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskot Clinical Trial using 4 doses of abatacept; 6 doses of abatacept

Emory University - Recruiting N/A to 21 years.
- Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Disease: a Dose Assessment Pilot.
4 doses of abatacept; 6 doses of abatacept

Aplastic Anemia, Leukemia, or Myelodysplastic Syndrome Clinical Trial using Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine.
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.; CliniMACS device

Chronic Renal Failure Requiring Hemodialysis Clinical Trial using Epoetin Hospira

Hospira, Inc. - Recruiting 18 years to 80 years.
- A Phase 3 Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment.
Epoetin Hospira

Sickle Cell Anemia Clinical Trial

St. Jude Children's Research Hospital - Recruiting 5 years to 19 years.
- State Of The Art Functional Imaging In Sickle Cell Disease.

Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Clinical Trial using Fetoscopic laser surgery

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- A Cluster Randomized Trial Comparing a Conservative Management and Primary Laser Surgery.
Fetoscopic laser surgery

Sickle Cell Disease Clinical Trial using G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sidney Kimmel Comprehensive Cancer Center - Recruiting 2 years to 70 years.
- A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Anemia and Other Hemoglobinopathies.
G-CSF; cyclophosphamide; fludarabine phosphate; mycophenolate mofetil; Sirolimus; Allogeneic bone marrow transplantation; total-body irradiation; Levetiracetam

Sickle Cell Anemia Clinical Trial using Measurement of carbon monoxide level in exhaled breath

Children's Hospital & Research Center Oakland - Recruiting 5 years to 14 years.
- Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis.
Measurement of carbon monoxide level in exhaled breath

Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplast Clinical Trial using Single arm MRI test

Novartis - Recruiting 12 years or older.
- An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study).
Single arm MRI test

Myelodysplastic Syndrome (MDS), or Severe Aplastic Anemia (SAA) Clinical Trial using Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 75 years.
- Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy.
Umbilical Cord Blood; Haploidentical Stem Cells; Miltenvi CliniMACs CD34 Reagent System

Sickle Cell Anemia Clinical Trial using Regadenoson; Regadenoson Placebo

Dana-Farber Cancer Institute - Recruiting 18 years to 70 years.
- A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia.
Regadenoson; Regadenoson Placebo

Anemia, or Blood Disease Clinical Trial

North Shore Long Island Jewish Health System - Recruiting N/A or older.
- Diamond Blackfan Anemia Registry (DBAR).

Leukemia Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- CHOP Plus Rituximab (CHOP-R) in Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL) or CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT).
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

Anemia, Leukemia, or Neutropenia Clinical Trial using fludarabine phosphate; methotrexate

National Cancer Institute (NCI) - Recruiting 18 years or older.
- First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL).
fludarabine phosphate; methotrexate

Thalassemia, or Sickle Cell Disease Clinical Trial using Medical Chart Summary

HaEmek Medical Center, Israel - Recruiting 5 years to 45 years.
- Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia.
Medical Chart Summary

Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome Clinical Trial using sirolimus

Children's Hospital of Philadelphia - Recruiting 1 year to 30 years.
- Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series.
sirolimus

Anemia, Hematologic Neoplasm, Neutropenia, Pancytopenia, or Throm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Screening Protocol for Subjects Being Evaluated for Hematology Branch Protocols.

Anemia, Iron-Deficiency, or Weight Loss Clinical Trial using Intravenous Iron sucrose; Oral Iron

Federal University of Sao Paulo - Recruiting 18 years to 55 years.
- Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial.
Intravenous Iron sucrose; Oral Iron

Hemorrhage, or Anemia Clinical Trial using Ferrous sulfate; Capsule Endoscopy

Medical University of South Carolina - Recruiting 18 years or older.
- Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding.
Ferrous sulfate; Capsule Endoscopy

Anemia, Sickle Cell, or Pain Clinical Trial using Fentanyl Citrate; Normal Saline

Montefiore Medical Center - Recruiting 3 years to 21 years.
- Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial.
Fentanyl Citrate; Normal Saline

Anemia Clinical Trial

iOMEDICO AG - Recruiting 18 years or older.
- Clinical Registry Describing Treatment Reality of Patients With Cancer-induced Anemia.

Myelodysplastic Syndrome, MDS, or Anemia Clinical Trial using Lenalidomide; Eltrombopag

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PHASE II STUDY OF LENALIDOMIDE AND ELTROMBOPAG IN PATIENTS WITH SYMPTOMATIC ANEMIA IN LOW OR INTERMEDIATE I MYELODYSPLASTIC SYNDROME (MDS).
Lenalidomide; Eltrombopag

Anemia Clinical Trial using FG-4592; Placebo

FibroGen - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
FG-4592; Placebo

Sickle Cell Disease, or Sickle Cell Anemia Clinical Trial using regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Blood Center of Wisconsin - Recruiting 18 years to 70 years.
- Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia.
regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound

Postpartum Anemia Clinical Trial using Iron isomaltoside 1000; Ferrous sulphate

Dow University of Health Sciences - Recruiting 18 years to 45 years.
- Iron Isomaltoside 1000 (Monofer).
Iron isomaltoside 1000; Ferrous sulphate

Dyskeratosis Congenita, Fanconi Anemia, Myelodysplastic Syndromes Clinical Trial using polymerase chain reaction; flow cytometry; immunologic technique; biopsy

University Hospital Freiburg - Recruiting N/A to 17 years.
- TCR Vbeta Repertoire and PNH Clones in Children With Refractory Cytopenia (RC). An Open Nonrandomised Multi-Center Prospective Study.
polymerase chain reaction; flow cytometry; immunologic technique; biopsy

Sickle Cell Disease Clinical Trial

Children's Hospital Los Angeles - Recruiting 13 years or older.
- Iron-mediated Vascular Disease in Sickle Cell Disease..

Anemia Clinical Trial using Control bread; Teff Bread

Manchester Metropolitan University - Recruiting 18 years to 40 years.
- Teff (Eragrostis Tef) as a Functional Food for the Prevention of Pregnancy Iron-deficiency Anemia.
Control bread; Teff Bread

Healthy Subjects, or Anemia Clinical Trial using Fundus photography, cubital blood draw

Triemli Hospital - Recruiting 18 years to 90 years.
- Non- Invasive Measurement of the Absolute Hemoglobin Value in the Retinal Arteries of Anemic and Healthy Subjects Using a New Approach.
Fundus photography, cubital blood draw

Anemia, Sickle Cell, or Transfusion Hemochromatosis Clinical Trial using deferasirox

Children's Hospital Los Angeles - Recruiting 14 years or older.
- Clinical Importance of Treating Iron Overload in Sickle Cell Disease.
deferasirox

Anemia, Aplastic Clinical Trial using Ex Vivo Immunotherapy; Ex vivo immunotherapy

Shenzhen Zhongxing Yangfan Biotech Co. Ltd. - Recruiting 10 years to 80 years.
- Phase I/II Study of An Ex Vivo Immunotherapy for Treatment of Idiopathic Aplastic Anemia.
Ex Vivo Immunotherapy; Ex vivo immunotherapy